title: [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
abstract: The Wnt pathway plays an important role in bone formation and regeneration, and expression of two Wnt pathway inhibitors, sclerostin and Dickkopf-1, appears to be associated with changes in bone mass. Inactivation of sclerostin leads to substantially increased bone mass in humans and in genetically manipulated animals. Studies in various animal models of bone disease have shown that inhibition of sclerostin using a monoclonal antibody increases bone formation, density, and strength. Clinical trials are ongoing to evaluate the effects of monoclonal antibodies to sclelostin in humans for the treatment of osteoporosis.
authors.affiliation: Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Soen
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D019485:Bone Morphogenetic Proteins / Q000276:immunology*; D002986:Clinical Trials as Topic; D005819:Genetic Markers / Q000276:immunology*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D060449:Wnt Signaling Pathway / Q000276:immunology
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human